A carregar...

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

BACKGROUND: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug interactions (DDIs) that could affect the efficacy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Drug Investig
Main Authors: Csonka, Dénes, Bruderer, Shirin, Schultz, Armin, Soergel, Marianne, Stepanova, Radka, Sabattini, Giancarlo, Perez-Ruixo, Juan Jose
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6842351/
https://ncbi.nlm.nih.gov/pubmed/31552642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00857-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!